Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Cross Below 200 Day Moving Average - Here's Why

Key Points

• Tarsus shares fell below their 200-day moving average, trading as low as $66.85 versus the average of $67.83.
• Third-quarter revenue increased 63.9% to about $194.6 million, led by record XDEMVY sales. The company forecast $715 million–$730 million in XDEMVY sales for 2026, but reported a wider net loss and deferred plans for European and Japanese filings.
• Analyst sentiment remains broadly positive: Tarsus has a “Moderate Buy” consensus rating and an average price target of $104.57.

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $67.83 and traded as low as $66.85. Tarsus Pharmaceuticals shares last traded at $67.52, with a volume of 1,715,283 shares traded.

Tarsus Pharmaceuticals News Summary

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 63.9% to about $194.5 million, with record sales of XDEMVY. Tarsus expects $715 million–$730 million in XDEMVY sales for 2026, supporting the growth outlook. Article: Tarsus expects $715M-$730M 2026 XDEMVY sales
• Positive Sentiment: Analysts raised price targets and maintained bullish ratings: Guggenheim lifted its target to $97 with a Buy rating, while Oppenheimer raised its target to $103 and kept an Outperform rating. Guggenheim rating Oppenheimer price target
• Neutral Sentiment: Management plans to participate in upcoming investor conferences; this may provide opportunities to discuss the business and outlook, but no new financial information was announced. Tarsus investor conference announcement
• Negative Sentiment: The quarterly net loss widened to $668 million, primarily due to acquisition-related costs, despite revenue growth. Tarsus also deferred European and Japanese filing plans, delaying potential international expansion. Q3 loss and XDEMVY sales Sales outlook and international filing plans

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Jefferies Financial Group raised their target price on shares of Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the company a "buy" rating in a research report on Tuesday, September 8th. The Goldman Sachs Group initiated coverage on shares of Tarsus Pharmaceuticals in a research report on Thursday, September 24th. They set a "buy" rating and a $116.00 price target on the stock. Zacks Research upgraded shares of Tarsus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Tuesday, October 13th. Barclays started coverage on Tarsus Pharmaceuticals in a research report on Wednesday, September 16th. They issued an "overweight" rating and a $110.00 target price on the stock. Finally, HC Wainwright upped their target price on Tarsus Pharmaceuticals from $88.00 to $106.00 and gave the stock a "buy" rating in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Tarsus Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $104.57.

Tarsus Pharmaceuticals Stock Down 2.2%

The company has a debt-to-equity ratio of 0.70, a current ratio of 1.96 and a quick ratio of 3.17. The firm's 50 day moving average is $75.06 and its two-hundred day moving average is $67.83. The firm has a market capitalization of $3.33 billion, a P/E ratio of -4.45 and a beta of 0.34.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($14.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.46) by ($12.94). Tarsus Pharmaceuticals had a negative return on equity of 24.51% and a negative net margin of 102.93%. The firm had revenue of $194.57 million for the quarter, compared to the consensus estimate of $187.83 million. Research analysts predict that Tarsus Pharmaceuticals, Inc. will post -2.23 EPS for the current year.

Insider Activity at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 10,000 shares of Tarsus Pharmaceuticals stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $90.56, for a total value of $905,600.00. Following the completion of the sale, the chief executive officer owned 827,991 shares in the company, valued at $74,982,864.96. The trade was a 1.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Lin sold 10,773 shares of the business's stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $87.50, for a total transaction of $942,637.50. Following the completion of the sale, the insider directly owned 2,547 shares of the company's stock, valued at $222,862.50. This represents a 80.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 48,031 shares of company stock worth $4,004,227. Corporate insiders own 9.64% of the company's stock.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC increased its holdings in Tarsus Pharmaceuticals by 16.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 151,606 shares of the company's stock valued at $11,440,000 after buying an additional 21,277 shares during the period. Alps Advisors Inc. boosted its position in shares of Tarsus Pharmaceuticals by 34.0% during the 3rd quarter. Alps Advisors Inc. now owns 58,130 shares of the company's stock worth $4,570,000 after acquiring an additional 14,765 shares in the last quarter. Covestor Ltd increased its stake in Tarsus Pharmaceuticals by 40.0% in the third quarter. Covestor Ltd now owns 1,095 shares of the company's stock valued at $86,000 after acquiring an additional 313 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Tarsus Pharmaceuticals during the third quarter valued at approximately $185,000. Finally, Profund Advisors LLC raised its position in Tarsus Pharmaceuticals by 288.1% during the third quarter. Profund Advisors LLC now owns 19,378 shares of the company's stock valued at $1,523,000 after purchasing an additional 14,385 shares in the last quarter. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye diseases with significant unmet medical needs. The company's portfolio is centered on therapies designed to address conditions affecting the ocular surface and eyelids.

Tarsus' lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, an inflammatory eyelid condition associated with an infestation of Demodex mites.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.